FluoroPharma Inc., a Boston molecular imaging agents developer, has named Thijs Spoor as CEO of the company. Spoor has also taken a seat on the board of directors.
The new CEO’s background includes most recently a position as chief financial officer of Sunstone BioSciences Inc., an optical nanomaterials company. He spent 15 years working in global roles involving regulatory affairs, new product development and as global brand head for nuclear cardiology at (Amersham) GE Healthcare. His financial career background includes coverage of biotechnology and medical device stocks while working for J.P. Morgan and Credit Suisse.